“showed a trend”

High consumption of B12 showed a trend relationship to poor cognitive performance (p=O.056), contrasting with lower serum B12 levels(p=0.075).

Plasma IGFBP-2 levels correlated with CSF t-tau levels (r = 0.11, p = 0.040) and showed a trend with p-tau levels (r = 0.09, p = 0.075).

The expression of In1-ghrelin variant was not correlated with the presence of ER or PR in this series but showed a trend to be correlated with Her2neu presence, so that the expression level of In1-ghrelin is numerically, albeit non-significantly (p = 0.075), higher in Her2neu tumors compared with luminal and basal tumors (data not shown).

The DAT showed a trend to be longer after 16 weeks of treatment ( p = 0.075) and was significantly longer at week 20 ( p = 0.044) when compared to baseline.

In men, repeated-measures analysis showed a trend toward a positive association between average Z and CBF ( r rm = 0.509, P = 0.075), but this association was not evident in the Δ-based Pearson correlations (Δ Z vs ΔCBF: r = 0.269, P = 0.158).

Histopathological aggressiveness features—perineural invasion (PNI; 73.0% in the entire cohort) and vascular invasion (VI; 62.6%)—were relatively evenly distributed, although PNI showed a trend toward a higher incidence in PB (81.8% vs. 63.5% in the PN; p = 0.075), which, however, did not reach significance after adjustment.

Only the Emotional Symptoms scale showed a trend difference (p = 0.075; η = 0.220; η 2 = 0.048), with higher scores for onco-hematology and pulmonology patients and lower scores for gastroenterology patients (Table 5 ).

Our supplementary analyses showed a trend toward positive correlation between E2 decline and PCC compensation (r=0.376, p=0.075), indicating the PCC prioritizes compensation to preserve memory function amid E2 loss.

The LN+ group showed a trend toward higher Risk-Score compared to the LN- group, with median values of 93.0 and 76.8, respectively ( p = 0.075) (Fig. 4 a).

MD+SPS animals receiving DK‐I‐56‐1 traveled a longer distance (adjusted p = 0.0361, q = 3.901; Figure 2a ) and showed a trend toward more rotations (adjusted p = 0.075, q = 3.479; Figure S2 ) compared with MD+SPS‐VEH.

Resistant models showed a trend towards enrichment with neuroendocrine cells ( P = 0.075), a significant depletion with enteric neuron cells ( P = 0.04) and a trend towards lower levels of enterocytes and paneth cells ( P = 0.078 and 0.4, respectively) as compared to sensitive models (Suppl.

5B ), and also showed a trend toward improved OS (NR vs 10.3 months; HR = 4.03, 95% CI: 0.78–20.91; P = 0.075; Fig. 5C ).

Pathologically confirmed lymph node-positive (pN +) patients showed a trend toward lower OS ( P = 0.075) and had significantly worse DFS ( P < 0.05) compared to pN − patients (Fig. 5 C and D).

Additionally, MD‐CMML patients with MLR > 1 showed a trend toward a higher prevalence of CBL mutations (17.9% vs. 6.7%; P = 0.075).

Among patients with complete NOTCH1 and IGHV data (n=225), NOTCH1 m showed a trend toward worse survival in IGHV-mutated patients (HR=3.26, 95% CI: 0.89–11.94, p=0.075) but not in IGHV-unmutated patients (HR=1.29, 95% CI: 0.63–2.65, p=0.49).

Although not statistically significant, sarcopenia in male patients showed a trend toward higher 30-day complication risk (odds ratio [OR]: 2.10, P = 0.075), suggesting a possible association that merits further evaluation.

Male sex showed a trend towards higher risk of AP (OR = 3.13; 95%- CI: 0.93–11.86; p = 0.075).

Although the primary endpoint of OS did not meet the predefined threshold of statistical significance (HR 0.83, p=0.0419), nivolumab showed a trend towards improved median OS (16.4 vs. 14.7 months; HR 0.85, p=0.0752) and ORR (15% vs. 7%) compared to sorafenib.

Patients with a high sPD-L1 level after CRT showed a trend for worse disease-free survival (DFS) than those with a low sPD-L1 level (p = 0.0752); although, the p-value did not reach statistical significance ( Fig 2B ).

The survival rates showed a trend toward improvement in the young PD‐L1 mAb‐treated group compared to aged mice ( p = 0.0753) (Figure 3B ).

Although the T2-based model showed a trend towards better performance compared to the T1 and T2-FLAIR models, these differences did not reach statistical significance (P-value = 0.0753 and P-value = 0.0892, respectively).

Quantitative analysis showed a trend toward improved hepatic perfusion following healthy-donor FMT that did not reach statistical significance ( p = 0.0754).

In follow-up exploratory, hypothesis-generating analyses, children with ASD showed a trend toward increased SW from DR to EO ( z = 1.78, p = 0.0756), whereas TD children displayed a trend in the opposite direction ( z = −1.91, p = 0.0567).

Supporting these observations, average cell volumes were decreased 32% by GREB1 overexpression ( p = 0.0016) and showed a trend for 148% increase with GREB1 knockdown ( p = 0.0756; Figure S4 ).

In addition, live measurements of the oxygen tension in the spinal cord grey matter of anaesthetized rats showed a trend ( p = 0.0759) of decreased oxygen concentration in rats with passive EAE (at the peak of disease, score 5) compared with RPMI‐treated healthy controls (Figure S1A,B ).